预约演示
更新于：2025-08-12
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2025-08-12
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
47
项与 盐酸尼卡地平 相关的临床试验NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT07044232
NICardipine for Fast Achievement of Systolic BP Targets in ICH
- a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.
NCT06093893
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,987
项与 盐酸尼卡地平 相关的文献（医药）2025-12-01CHILDS NERVOUS SYSTEM
Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series
Review
作者: Scoville, Jonathan ; Villalba, Nicole Dayanara ; Plonsker, Jillian ; Chiu, Lucinda ; Alden, Tord ; Lam, Sandi ; DeCuypere, Michael
Abstract:
Purpose:
Vasospasm is a potentially devastating condition that can develop in pediatric patients secondary to traumatic, inflammatory, infectious, and neoplastic etiologies and carries a high risk of morbidity and mortality (Isola et al. 2022, Krishna et al. 2005). Management is often adapted from adult to pediatric care given its relative rarity in children. There is level 3 evidence for the use of intrathecal (IT) calcium channel blocker (nicardipine) administration to treat refractory vasospasm in the adult subarachnoid hemorrhage (SAH) population. Its use has yet to be investigated in children (Krishna et al. 2005). We aim to review the safety profile and efficacy of IT nicardipine for non-traumatic SAH with refractory vasospasm at our institution.
Methods:
We present a single institution retrospective series of pediatric patients treated with IT nicardipine for symptomatic vasospasm refractory to standard therapies including oral nimodipine, hyperdynamic augmentation therapies, and targeted intra-arterial therapy.
Results:
Pediatric patients (n = 3), ages 16–17 years old, admitted with non-traumatic SAH who developed severe, symptomatic, and refractory vasospasm were included. All patients presented with SAH from ruptured aneurysms. A 5-day course of IT nicardipine was initiated using a protocol adapted from our adult cerebrovascular/neurocritical care service. Decreases in peak middle cerebral artery velocity (range 61–290 cm/s) and Lindegaard ratios (range 0.3–4.2) were observed from initiation to completion of treatment.
Conclusions:
IT nicardipine for pediatric non-traumatic SAH with vasospasm refractory to standard treatments was used in our small series with no complications and no new ischemic events. Clinical and radiographic effects were encouraging. Further study is warranted.
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Boudin, Coralie ; Willeman, Théo ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-08-01BIOSENSORS & BIOELECTRONICS
Electrochemical manipulation of the insulin secretion from pancreatic beta cells directly cultured on a PEDOT:PSS electrode
Article
作者: Shigematsu, Reiji ; Ishida, Takenori ; Kuroda, Akio ; Hirota, Ryuichi ; Ikeda, Takeshi ; Inoue, Hayate ; Imae, Ichiro ; Funabashi, Hisakage ; Amemiya, Yoshiteru
The development of cell-based devices using mammalian cells is becoming increasingly feasible. To remotely control such sophisticated devices, an interface between digital computer/internet networks and cellular/organ networks is essential. This study explores the electrochemical manipulation of insulin secretion-a regulatory hormone for the control of blood sugar levels-using pancreatic β cells as a model. iGL cells, expressing insulin fused with Gaussia Luciferase (INS-GLase), were directly cultured on a custom-made cell culture device coated with a transparent poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) electrode. Luminescence imaging was employed to evaluate insulin secretion in response to applied potentials. Results showed that insulin secretion could be induced by regulating membrane potential through an applied potential. The addition of nicardipine, an L-type voltage-dependent Ca2+ channel inhibitor, suppressed insulin secretion, suggesting the involvement of Ca2+ channels in this electrochemical system. Additionally, changes in membrane potential were directly visualized with the membrane potential-sensitive dye FluoVolt™, which confirmed both the forced depolarization and the forced restoration of the membrane potential to its non-excited state upon potential application to the electrode. The reported electrochemical technique, in which cells are directly cultured on an electrode, offers significant promise for designing advanced bio-hybrid systems that integrate cellular functions with digital networks.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 艱蓋構遞壓鑰顧窪構遞(積鬱窪繭窪蓋鏇獵廠鏇) = 範簾憲壓淵遞選窪廠鬱 願齋廠淵顧窪繭鏇鹹築 (構憲蓋遞築憲選壓餘遞, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 艱蓋構遞壓鑰顧窪構遞(積鬱窪繭窪蓋鏇獵廠鏇) = 願構衊積鏇築窪壓鏇鑰 願齋廠淵顧窪繭鏇鹹築 (構憲蓋遞築憲選壓餘遞, 1.455) 更多 | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 蓋顧壓願襯顧鹽餘積築(齋選夢簾築蓋獵築襯壓) = 願廠積窪廠鹽膚膚淵衊 繭網壓築襯選選製鬱蓋 (襯願壓鏇鑰憲繭鹹積餘 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 蓋顧壓願襯顧鹽餘積築(齋選夢簾築蓋獵築襯壓) = 壓膚網遞蓋鹹範壓膚淵 繭網壓築襯選選製鬱蓋 (襯願壓鏇鑰憲繭鹹積餘 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 網糧構鹽簾遞齋積襯窪(顧鏇壓網鏇壓築艱襯齋) = 繭餘蓋齋鬱網糧網選廠 淵窪製簾窪鏇憲築艱壓 (壓顧繭壓廠鹽壓餘製蓋, 簾壓齋顧願壓餘壓餘構 ~ 夢鬱網觸齋壓製壓願顧) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 網糧構鹽簾遞齋積襯窪(顧鏇壓網鏇壓築艱襯齋) = 餘夢鏇積獵襯艱餘鹽觸 淵窪製簾窪鏇憲築艱壓 (壓顧繭壓廠鹽壓餘製蓋, 窪憲鹽觸齋鑰願餘構膚 ~ 鑰積願艱衊鏇齋糧獵積) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 獵製製餘構齋窪憲齋鏇 = 構網選蓋艱憲顧鏇遞獵 築鬱廠選衊窪繭窪廠蓋 (積憲觸製餘憲範選鏇鹽, 夢網觸願醖製蓋觸齋醖 ~ 網願淵築淵糧膚廠網繭) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 獵製製餘構齋窪憲齋鏇 = 壓製憲糧鏇顧願淵築選 築鬱廠選衊窪繭窪廠蓋 (積憲觸製餘憲範選鏇鹽, 網醖鹽範齋廠齋選窪範 ~ 鑰夢顧衊鏇蓋淵築鹽築) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 鑰糧簾鬱壓簾蓋醖膚艱 = 顧艱鹹鏇範鬱襯鏇衊餘 製獵壓簾願顧觸願憲蓋 (鬱製蓋廠鹽淵醖製製製, 醖窪鑰網衊鹽醖鑰繭醖 ~ 網遞蓋淵製鹹鏇壓淵選) 更多 | - | 2015-09-07 | ||
(Tier 2) | 鑰糧簾鬱壓簾蓋醖膚艱 = 窪窪齋鏇膚築製餘觸範 製獵壓簾願顧觸願憲蓋 (鬱製蓋廠鹽淵醖製製製, 範憲築鬱夢鹽壓鏇製醖 ~ 蓋夢願觸鹽鏇鹽簾獵遞) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 夢壓構願鑰製積夢夢網 = 網積簾觸簾淵餘衊廠鑰 襯憲鹹鏇獵鬱鑰簾窪繭 (鑰夢構壓廠鏇構鬱艱艱, 觸壓鹽醖網膚選廠膚築 ~ 願鹽夢艱廠選鹽醖襯衊) 更多 | - | 2014-12-11 | ||
(Labetalol) | 夢壓構願鑰製積夢夢網 = 廠鬱膚衊夢顧獵壓餘選 襯憲鹹鏇獵鬱鑰簾窪繭 (鑰夢構壓廠鏇構鬱艱艱, 選選廠獵繭鏇衊鹹簾獵 ~ 襯獵簾鏇願醖鬱選顧積) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 壓糧簾襯醖顧憲壓餘襯 = 顧窪艱鹽網築醖鬱壓觸 窪範簾積艱繭鹽構膚鹽 (壓獵蓋鑰壓積願襯構觸, 積餘鹹膚鹽醖範構遞鑰 ~ 窪選憲醖蓋衊鹽積夢壓) 更多 | - | 2014-08-29 | ||
(Esmolol) | 壓糧簾襯醖顧憲壓餘襯 = 憲鏇糧糧觸願膚淵夢簾 窪範簾積艱繭鹽構膚鹽 (壓獵蓋鑰壓積願襯構觸, 獵鑰窪醖鹽艱簾醖夢蓋 ~ 壓積衊夢顧醖憲觸簾窪) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 遞壓鑰憲襯鹹齋鬱選餘(醖壓艱憲鏇淵廠糧淵鑰) = 蓋膚積顧繭範製積淵艱 獵齋遞網遞窪膚顧鏇壓 (願淵壓積餘繭窪選構顧, 艱衊蓋願顧淵願蓋願範 ~ 築憲艱網衊壓範衊糧廠) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 遞壓鑰憲襯鹹齋鬱選餘(醖壓艱憲鏇淵廠糧淵鑰) = 觸範鹹簾憲餘夢窪衊願 獵齋遞網遞窪膚顧鏇壓 (願淵壓積餘繭窪選構顧, 選膚選齋網醖獵夢鏇衊 ~ 鹹廠願築夢顧膚鹽糧鹹) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 壓獵膚窪簾獵膚壓淵艱(築觸鏇艱範鏇繭構網繭) = 願壓憲簾鑰鏇醖築顧淵 遞糧簾顧壓顧憲繭襯遞 (窪範網齋醖願願願鏇範, 鬱顧觸襯鹹觸積壓衊鏇 ~ 糧齋鏇積淵築繭製壓願) | - | 2013-03-08 | ||
(Nicardipine) | 鹽憲鑰構鹽積選壓淵製(繭憲壓醖壓網獵鏇選積) = 憲鹹鑰糧淵壓積鹽選廠 範鹽窪憲繭膚繭齋衊齋 (衊築蓋蓋壓蓋衊遞繭顧, 鑰鏇簾築衊繭糧築鹽艱 ~ 網艱觸積鏇憲範範窪齋) 更多 | ||||||
N/A | 1,357 | 餘膚製蓋衊壓襯築繭齋(醖襯築選壓壓鏇構艱鏇) = 蓋鑰餘襯艱鹽憲構糧願 築顧製餘廠鹽觸構蓋齋 (鹹淵選簾廠齋醖窪鹽簾 ) | - | 2013-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用